Valuation: Supernus Pharmaceuticals, Inc.

Market Cap 2.37B 2.12B 1.96B 1.78B 3.32B 225B 3.38B 23.59B 9.33B 118B 8.89B 8.7B 373B P/E 2026 *
-177x
P/E 2027 * 36.3x
Enterprise Value 2.37B 2.12B 1.96B 1.78B 3.32B 225B 3.38B 23.59B 9.33B 118B 8.89B 8.7B 373B EV / Sales 2026 *
2.71x
EV / Sales 2027 * 1.74x
Free-Float
95.68%
Yield 2026 *
-
Yield 2027 * -
1 day+0.17%
1 week+2.33%
Current month-5.27%
1 month-4.43%
3 months-11.75%
6 months-18.07%
Current year-17.97%
1 week 39.58
Extreme 39.575
42.09
1 month 37.54
Extreme 37.54
44.93
Current year 37.54
Extreme 37.54
59.68
1 year 37.54
Extreme 37.54
59.68
3 years 23.04
Extreme 23.045
59.68
5 years 21.99
Extreme 21.99
59.68
10 years 13.12
Extreme 13.12
61.25
Manager TitleAgeSince
Chief Executive Officer 64 22/12/2005
Director of Finance/CFO 67 23/08/2021
Compliance Officer 63 01/01/2012
Director TitleAgeSince
Director/Board Member 64 22/12/2005
Chairman 81 10/08/2016
Director/Board Member 80 16/11/2010
Date Insider Type Main position Quantity % Market Cap. Importance
12/8/26 Exercice

Chief Technology Officer

4,097 0.0073%
12/8/26 Exercice

Chief Financial Officer

3,104 0.0055%
12/8/26 Exercice

Founder

72,340 0.1290%
Change 5-day change 1-year change 3-year change Capi.($)
+0.17%+2.33%-22.83%+79.45% 2.37B
+0.45%+3.13%+54.96%+125.16% 1,140B
+0.94%+4.93%+39.86%+78.72% 641B
+0.39%+1.44%+25.77%+97.48% 507B
+1.43%+4.31%+46.20%+67.12% 383B
-3.21%-2.10%+60.72%+33.22% 347B
-0.41%+2.64%+22.48%+49.82% 293B
+0.23%+3.66%+2.57%+23.69% 266B
+1.22%+4.63%+52.40%+64.85% 240B
+1.70%+3.67%+31.21%+102.15% 197B
Average +0.26%+2.86%+31.33%+72.17% 401.62B
Weighted average by Cap. +0.44%+2.98%+41.33%+83.80%

Financials

2026 *2027 *
Net sales 874M 782M 723M 655M 1.23B 83.15B 1.25B 8.7B 3.44B 43.49B 3.28B 3.21B 138B 1.36B 1.21B 1.12B 1.02B 1.9B 129B 1.94B 13.53B 5.35B 67.61B 5.1B 4.99B 214B
Net income -13.38M -11.97M -11.07M -10.02M -18.76M -1.27B -19.07M -133M -52.69M -666M -50.22M -49.15M -2.11B 65.41M 58.49M 54.11M 49M 91.7M 6.22B 93.2M 651M 258M 3.25B 245M 240M 10.31B
Net Debt - -
Projected Income Statement - Annual - Supernus Pharmaceuticals, Inc.
Logo Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The Company is developing a range of CNS product candidates including new potential treatments for epilepsy, depression, ADHD, and other CNS disorders. Its products marketed in the United States include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC, ONAPGOTM (formerly known as SPN-830), and ZURZUVAE. Qelbree (viloxazine extended-release capsules) is a non-stimulant product indicated for the treatment of ADHD in adults and pediatric patients 6 years and older.
Employees
778
Date Price Change Volume
26/10/26 US$40.77 +0.17% 930,903
23/10/26 US$40.70 -3.26% 1,159,336
22/10/26 US$42.07 +2.09% 937,419
21/10/26 US$41.21 -0.05% 1,006,298
20/10/26 US$41.23 +3.49% 1,240,345
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Supernus Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
40.77USD
Average target price
60.50USD
Spread / Average Target
+48.39%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Supernus Pharmaceuticals, Inc.
  1. Stock Market
  2. Stocks
  3. SUPN Stock